-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, many traditional pharmaceutical companies have gradually developed innovative drugs, and Simcere has also continued to make innovations in medicine
.
Statistics show that the proportion of Simcere's R&D investment in 2020 has risen from less than 10% in 2018 to 25.
3%, and in the first half of 2021 it will be close to 30%
.
With the increase in R&D investment, Simcere's new products are also constantly on the market
.
There are currently seven drugs Envolimab (envafolimab), edaravone (edaravone), fluorouracil (fluorouracil), abatacept (abatacept), iguratimod (iguratimod), trilaciclib dihydrochloride, zanamivir (zanamivir) was launched
.
It is reported that with the launch of new products and increased volume, Simcere's innovative drug revenue accounted for a record high, reaching 57.
6% in the first half of 2021, far exceeding the industry's average of 13%
.
Recently, Simcere Pharmaceuticals has made frequent reports of new drug development and advancement
.
On December 6, the new anti-tumor drug SIM1811-03 injection (SIM0235) was approved.
Simcere Pharmaceuticals issued an announcement.
On December 6, 2021, the group’s self-developed humanized anti-tumor necrosis factor type 2 receptor ( TNFR2) monoclonal antibody SIM0235 (SIM1811-03 injection) has obtained a drug clinical trial approval notice issued by the National Medical Products Administration of China, and it is planned to be used for the development of relapsed or refractory advanced solid tumors and cutaneous T-cell lymphoma (CTCL) ) Clinical trials
.
SIM0235 is a human immunoglobulin G1 (IgG1) type humanized anti-TNFR2 monoclonal antibody
.
It can specifically recognize TNFR2 expressed on the cell surface, through antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and other Fc-terminal functions.
Immunosuppressive cells such as regulatory T cells (Treg) and bone marrow-derived suppressor cells (MDSC) play a killing effect.
At the same time, it can also inhibit the activation of TNFR2 by endogenous tumor necrosis factor (TNF) and inhibit TNFR2-mediated The immunosuppressive function and the proliferation of related TNFR2+ immunosuppressive cells Treg and MDSC can enhance the body's anti-tumor immune response and exert anti-tumor effects
.
On November 29th, the innovative drug Trirazil for injection, which cooperated with GI, submitted a marketing application to NMPA and was accepted.
On November 29th, Simcere announced that it had submitted a new drug for bone marrow-protecting innovative drug Trirazile for injection to NMPA.
The listing application has been accepted
.
This is a CDK 4/6 inhibitor introduced by Simcere from G1 Therapeutics for US$170 million
.
It took 15 months from the introduction to the submission of the NDA .
The indications applied for in China this time are: prophylactic use in patients with extensive-stage small cell lung cancer receiving platinum-containing drugs combined with etoposide to reduce the incidence of bone marrow suppression caused by chemotherapy
.
On November 25, the PD-L1 subcutaneous injection envolimab, which is cooperating with Siddi and Corning Jereh, was conditionally launched in China.
On Nov.
25, Simcere Pharmaceuticals, Siddi Medicine, and Corning Jereh Biopharmaceutical jointly announced , The PD-L1 single-domain antibody Envida (Envolimab injection), which is a strategic cooperation of the three parties, was officially approved by the National Medical Products Administration (NMPA) (Approval number: National Medicine Standard S20210046)
.
As a subcutaneous injection of PD-L1 antibody, Envida solves the unmet clinical needs of tumor patients who are intolerant to intravenous administration, and saves a lot of treatment time compared with intravenous administration, and avoids various adverse reactions of intravenous infusion.
.
Simcere said that Envida is an innovation in the field of tumor immunotherapy in China.
A more convenient and safer method of subcutaneous injection will bring patients a better treatment experience and quality of life.
.
In addition, Simcere Pharmaceuticals has submitted and accepted clinical trial applications for breast cancer innovative drug SIM0270 and glioblastoma new drug SIM0395
.
Data shows that since 2021, Simcere's Oncology Pipeline has launched 185 clinical centers, managing more than 800 patients per month, and achieving the first patient medication in 7 projects
.
Global BD has reached 6 cooperation projects this year, and more than 10 of the nearly 60 innovative drugs under development are in the clinical stage
.
.
Statistics show that the proportion of Simcere's R&D investment in 2020 has risen from less than 10% in 2018 to 25.
3%, and in the first half of 2021 it will be close to 30%
.
With the increase in R&D investment, Simcere's new products are also constantly on the market
.
There are currently seven drugs Envolimab (envafolimab), edaravone (edaravone), fluorouracil (fluorouracil), abatacept (abatacept), iguratimod (iguratimod), trilaciclib dihydrochloride, zanamivir (zanamivir) was launched
.
It is reported that with the launch of new products and increased volume, Simcere's innovative drug revenue accounted for a record high, reaching 57.
6% in the first half of 2021, far exceeding the industry's average of 13%
.
Recently, Simcere Pharmaceuticals has made frequent reports of new drug development and advancement
.
On December 6, the new anti-tumor drug SIM1811-03 injection (SIM0235) was approved.
Simcere Pharmaceuticals issued an announcement.
On December 6, 2021, the group’s self-developed humanized anti-tumor necrosis factor type 2 receptor ( TNFR2) monoclonal antibody SIM0235 (SIM1811-03 injection) has obtained a drug clinical trial approval notice issued by the National Medical Products Administration of China, and it is planned to be used for the development of relapsed or refractory advanced solid tumors and cutaneous T-cell lymphoma (CTCL) ) Clinical trials
.
SIM0235 is a human immunoglobulin G1 (IgG1) type humanized anti-TNFR2 monoclonal antibody
.
It can specifically recognize TNFR2 expressed on the cell surface, through antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and other Fc-terminal functions.
Immunosuppressive cells such as regulatory T cells (Treg) and bone marrow-derived suppressor cells (MDSC) play a killing effect.
At the same time, it can also inhibit the activation of TNFR2 by endogenous tumor necrosis factor (TNF) and inhibit TNFR2-mediated The immunosuppressive function and the proliferation of related TNFR2+ immunosuppressive cells Treg and MDSC can enhance the body's anti-tumor immune response and exert anti-tumor effects
.
On November 29th, the innovative drug Trirazil for injection, which cooperated with GI, submitted a marketing application to NMPA and was accepted.
On November 29th, Simcere announced that it had submitted a new drug for bone marrow-protecting innovative drug Trirazile for injection to NMPA.
The listing application has been accepted
.
This is a CDK 4/6 inhibitor introduced by Simcere from G1 Therapeutics for US$170 million
.
It took 15 months from the introduction to the submission of the NDA .
The indications applied for in China this time are: prophylactic use in patients with extensive-stage small cell lung cancer receiving platinum-containing drugs combined with etoposide to reduce the incidence of bone marrow suppression caused by chemotherapy
.
On November 25, the PD-L1 subcutaneous injection envolimab, which is cooperating with Siddi and Corning Jereh, was conditionally launched in China.
On Nov.
25, Simcere Pharmaceuticals, Siddi Medicine, and Corning Jereh Biopharmaceutical jointly announced , The PD-L1 single-domain antibody Envida (Envolimab injection), which is a strategic cooperation of the three parties, was officially approved by the National Medical Products Administration (NMPA) (Approval number: National Medicine Standard S20210046)
.
As a subcutaneous injection of PD-L1 antibody, Envida solves the unmet clinical needs of tumor patients who are intolerant to intravenous administration, and saves a lot of treatment time compared with intravenous administration, and avoids various adverse reactions of intravenous infusion.
.
Simcere said that Envida is an innovation in the field of tumor immunotherapy in China.
A more convenient and safer method of subcutaneous injection will bring patients a better treatment experience and quality of life.
.
In addition, Simcere Pharmaceuticals has submitted and accepted clinical trial applications for breast cancer innovative drug SIM0270 and glioblastoma new drug SIM0395
.
Data shows that since 2021, Simcere's Oncology Pipeline has launched 185 clinical centers, managing more than 800 patients per month, and achieving the first patient medication in 7 projects
.
Global BD has reached 6 cooperation projects this year, and more than 10 of the nearly 60 innovative drugs under development are in the clinical stage
.
